<p>Association between <i>EGFR</i>-mutant status and Erlotinib treatment with all-cause survival among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.</p
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlle...
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced n...
Introduction:The phase III FLEX study (NCT00148798) in advanced non–small-cell lung cancer indicated...
<div><p>Despite being the basis of one of the most effective interventions in lung cancer, little is...
<p>Factors associated with receipt of Erlotinib among patients diagnosed in 2010 with stage IV non-s...
In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal...
Background:EGFR and KRAS mutations are mutually exclusive and predict outcomes with epidermal growth...
<p>Frequency of <i>EGFR</i> testing and receipt of erlotinib among non-small cell lung cancer patien...
The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of ...
<p>EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group performance stat...
IntroductionRelationships between clinical outcomes and epidermal growth factor receptor (EGFR)-rela...
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational stat...
IntroductionSomatic mutations in the epidermal growth factor receptor (EGFR) gene are associated wit...
Preclinical data suggest that combined EGF receptor (EGFR) targeting with an EGFR tyrosine kinase in...
‡<p>reference group was exon 21. <i>EGFR</i>: epidermal growth factor receptor, TKI: tyrosine kinase...
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlle...
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced n...
Introduction:The phase III FLEX study (NCT00148798) in advanced non–small-cell lung cancer indicated...
<div><p>Despite being the basis of one of the most effective interventions in lung cancer, little is...
<p>Factors associated with receipt of Erlotinib among patients diagnosed in 2010 with stage IV non-s...
In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal...
Background:EGFR and KRAS mutations are mutually exclusive and predict outcomes with epidermal growth...
<p>Frequency of <i>EGFR</i> testing and receipt of erlotinib among non-small cell lung cancer patien...
The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of ...
<p>EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group performance stat...
IntroductionRelationships between clinical outcomes and epidermal growth factor receptor (EGFR)-rela...
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational stat...
IntroductionSomatic mutations in the epidermal growth factor receptor (EGFR) gene are associated wit...
Preclinical data suggest that combined EGF receptor (EGFR) targeting with an EGFR tyrosine kinase in...
‡<p>reference group was exon 21. <i>EGFR</i>: epidermal growth factor receptor, TKI: tyrosine kinase...
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlle...
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced n...
Introduction:The phase III FLEX study (NCT00148798) in advanced non–small-cell lung cancer indicated...
DOI
Add to ORKG